🔮 Better than the Oracle? Our Fair Value found this +42% bagger 5 months before Buffett bought itRead More

Zymeworks Cancer Candidate Shows Objective Response Of 41% In Bile Duct Cancer

Published 19/12/2022, 18:36
© Reuters.  Zymeworks Cancer Candidate Shows Objective Response Of 41% In Bile Duct Cancer
IXIC
-
ZYME
-

Benzinga -

  • Zymeworks Inc (NASDAQ: ZYME) announced topline results from the pivotal Phase 2b HERIZON-BTC-01 trial investigating zanidatamab as monotherapy in patients with previously treated HER2-amplified and expressing biliary tract cancers (BTC).
  • In October, Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced to acquire rights to zanidatamab across all indications in the U.S., Europe, Japan, and all other territories except for those Asia/Pacific territories that Zymeworks previously licensed to BeiGene Ltd (NASDAQ: BGNE).
  • Related: Analyst Moves To Sidelines After Jazz Pharma Deal Shifts Zymeworks To Early Stage Pipeline.
  • The topline results showed that 41.3% of enrolled patients with HER2-amplified and expressing (IHC2+ and 3+) disease achieved an objective response.
  • The median duration of response was 12.9 months.
  • The safety profile of zanidatamab in this trial was consistent with that observed in previously reported monotherapy studies, with no new safety signals identified.
  • Price Action: ZYME shares are up 4.80% at $6.77 on the last check Monday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.